News Releases

2010
24/01/2010ASCO-GI: OVERALL SURVIVAL WITH ERBITUX IS SIGNIFICANTLY IMPROVED IN PATIENTS WITH KRAS WILD-TYPE TUMORS IN CRYSTAL
Geneva, Switzerland
 English 
21/01/2010TWO-YEAR RESULTS FROM CLARITY STUDY WITH CLADRIBINE TABLETS IN MULTIPLE SCLEROSIS PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
Geneva, Switzerland
 English
French
German
18/01/2010LE MAGAZINE BILAN PLACE MERCK SERONO EN TETE DE SON PALMARES 2010 DES MEILLEURS EMPLOYEURS DE SUISSE ROMANDE
Geneva, Switzerland
French
2009
16/12/2009MERCK SERONO ANNOUNCES COLLABORATION IN BASIC AND CLINICAL RESEARCH IN MULTIPLE SCLEROSIS
Geneva, Switzerland
 English
French
German
10/12/2009

MERCK SERONO STARTS STIMUVAX PHASE III STUDY INSPIRE IN ASIAN PATIENTS WITH ADVANCED NSCLC
Geneva, Switzerland

 English
10/12/2009MERCK Serono Initiates KAMPER, The First Pan-European Registry for Patients Under Kuvan® therapy
Geneva, Switzerland
 English
French
German
30/11/2009MERCK SERONO RECEIVES REFUSE TO FILE LETTER FROM FDA ON CLADRIBINE TABLETS NEW DRUG APPLICATION
Geneva, Switzerland
 English
French
German
25/11/2009MERCK SERONO LAUNCHES NEW WEBSITE ON PHENYLKETONURIA
Geneva, Switzerland
 English
French
German
19/11/2009MERCK SERONO TO EXPAND RESEARCH AND DEVELOPMENT PRESENCE IN CHINA
Geneva, Switzerland
 English
French
German
19/11/2009MERCK SERONO: CHMP OPINION FOR ERBITUX IN ADVANCED NON-SMALL CELL LUNG CANCER
Geneva, Switzerland
 English
16/11/2009

ERBITUX RECOGNIZED BY ASCO AS A 2009 MAJOR CANCER ADVANCE AS FIRST SCCHN TREATMENT TO IMPROVE SURVIVAL IN 30 YEARS
Geneva, Switzerland

 English
06/11/2009PETACC-8 STUDY INVESTIGATING ERBITUX AS ADJUVANT TREATMENT IN COLON CANCER COMPLETES RECRUITMENT
Geneva, Switzerland
 English
15/10/2009MERCK SERONO REÇOIT LE PRIX DE L’INDUSTRIE DE GENEVE
Geneva, Switzerland
 French
05/10/2009MERCK SERONO NAMED AS A TOP EMPLOYER BY SCIENCE MAGAZINE
Geneva, Switzerland
 English
French
German
30/09/2009MERCK SERONO SUBMITS APPLICATION FOR CLADRIBINE TABLETS AS A POTENTIAL ORAL SHORT-COURSE MULTIPLE SCLEROSIS THERAPY IN THE UNITED STATES
Geneva, Switzerland
 English
French
German
23/09/2009INITIAL COIN STUDY RESULTS PRESENTED AT EUROPEAN ONCOLOGY CONGRESS
Geneva, Switzerland
 English
16/09/2009MERCK SERONO GROWTH HORMONE INJECTION DEVICE EASYPOD® APPROVED IN JAPAN
Geneva, Switzerland
 English
French
German
14/09/2009RESULTS OF REBISMART™ USER TRIAL PRESENTED AT 25TH ECTRIMS CONGRESS SHOW BROAD PATIENT ACCEPTANCE OF THE NEW ELECTRONIC DELIVERY DEVICE FOR RELAPSING MULTIPLE SCLEROSIS TREATMENT REBIF®
Geneva, Switzerland
 English
French
German
11/09/2009Results from IMPROVE Study Show MRI Benefits of Rebif® Seen Early in Relapsing-Remitting Multiple Sclerosis Treatment and Sustained Over Time
Geneva, Switzerland
 English
French
German
11/09/2009NEW DATA FROM CLARITY STUDY ON DISEASE ACTIVITY IN MS PATIENTS WHO RECEIVED CLADRIBINE TABLETS PRESENTED AT 25TH ECTRIMS CONGRESS
Düsseldorf, Germany, and Geneva, Switzerland
 English
French
German
10/08/2009EMD SERONO, INC. AND THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ANNOUNCE COLLABORATION FOR PRECLINICAL RESEARCH AND CLINICAL TRIALS
Darmstadt, Germany
 English
04/08/2009DATA PRESENTED ON MERCK SERONO’S CILENGITIDE SUPPORT ONGOING CLINICAL EVALUATION IN NSCLC
San Francisco, CA, USA/Darmstadt Germany
 English
02/08/2009Merck Serono Presented New Data On the Combination of Erbitux with Standard First-Line Therapy in Patients with NSCLC
San Francisco, CA, USA / Geneva, Switzerland
 English
31/07/2009MERCK SERONO Has Requested Re-examination of the CHMP Opinion for Erbitux in Non-Small Cell Lung Cancer
Geneva, Switzerland
 English
24/07/2009MERCK SERONO CONSIDERS APPEALING CHMP OPINION ON ERBITUX TREATMENT FOR NON-SMALL CELL LUNG CANCER
Geneva, Switzerland
 English
23/07/2009MERCK SERONO SUBMITS APPLICATION FOR CLADRIBINE TABLETS
AS MULTIPLE SCLEROSIS THERAPY IN EUROPE
Geneva, Switzerland
 English
French
German
16/07/2009GONAL-F APPROVED IN JAPAN FOR OVULATION INDUCTION IN INFERTILE WOMEN
Geneva, Switzerland
 English
French
German
15/07/2009MERCK SERONO ANNOUNCES LICENSE AGREEMENT WITH BIOWA FOR POTELLIGENT® TECHNOLOGY
Darmstadt, Germany
 English
01/07/2009MERCK SERONO LAUNCHES “GLOBAL FERTILITY ACADEMY” TO PROVIDE EDUCATION AND TRAINING FOR THE TREATMENT OF INFERTILITY
Geneva, Switzerland
 English
French
German 
24/06/2009MERCK SERONO: LATEST ERBITUX DATA ON METASTATIC COLORECTAL CANCER PRESENTED AT WCGIC UNDERLINE BENEFITS IN PATIENTS WITH KRAS WILD-TYPE TUMORS
Barcelona, Spain/Darmstadt, Germany
 English
24/06/2009MERCK SERONO LAUNCHES REBISMART™, FIRST ELECTRONIC INJECTION DEVICE FOR DELIVERY OF MULTIPLE SCLEROSIS TREATMENT REBIF®
Geneva, Switzerland
 English
French
German
Italian
22/06/2009NEW DATA FROM CLARITY STUDY PRESENTED AT 19TH ENS MEETING SHOW RAPID AND SUSTAINED MS RELAPSE REDUCTION FOR CLADRIBINE TABLETS
Geneva, Switzerland
 English
French
German
Italian
22/06/2009MERCK SERONO INITIATES PHASE III STUDY OF STIMUVAX IN BREAST CANCER
Geneva, Switzerland
 English
03/06/2009

FIRST PHASE III CLINICAL TRIAL RESULTS OF SAFINAMIDE IN ADVANCED PARKINSON’S DISEASE TO BE PRESENTED AT THE MOVEMENT DISORDER SOCIETY 13TH INTERNATIONAL CONGRESS
Geneva, Switzerland

 English
French
German
01/06/2009UK’S NICE RECOMMENDS USE OF ERBITUX FOR METASTATIC COLORECTAL CANCER PATIENTS
Geneva, Switzerland
 English
31/05/2009MERCK SERONO AT FOREFRONT OF EXPLORING MARKERS OF RESPONSE IN CONTINUED EFFORT TO PERSONALIZE CANCER CARE
Orlando, FL, USA / Geneva, Switzerland
 English
31/05/2009STUDY SHOWS CILENGITIDE INCREASED OVERALL SURVIVAL IN PATIENTS WITH GLIOBLASTOMA
Orlando, FL, USA / Geneva, Switzerland
 English
30/05/2009FOLLOW-UP FROM STIMUVAX STUDY PROVIDES LONG-TERM SAFETY DATA IN ADVANCED LUNG CANCER PATIENTS RECEIVING TREATMENT FOR UP TO 8.2 YEARS
Orlando, FL, USA / Geneva, Switzerland
 English
25/05/2009MERCK SERONO To Support First International Thyroid Awareness Week
Geneva, Switzerland
 English
French
German
18/05/2009MERCK SERONO COMMITTED TO INVESTING IN INNOVATION IN THE FERTILITY AREA
Geneva, Switzerland
 English
French
German
14/05/2009MERCK SERONO CHAMPIONS PERSONALIZED CANCER CARE WITH TARGETED THERAPIES
Darmstadt, Germany
 English
07/05/2009RESULTS AT ASCO CONGRESS 2009 HIGHLIGHT MERCK SERONO'S LEADERSHIP IN PERSONALIZING CANCER CARE
Geneva, Switzerland
 English
07/05/2009MERCK SERONO INITIATES SETTLE, THE SECOND PHASE III CLINICAL TRIAL OF SAFINAMIDE IN ADVANCED PARKINSON’S DISEASE
Geneva, Switzerland
 English
French
German
05/05/2009Merck Serono Launches Glucophage Powder in First European Countries
Geneva, Switzerland
 English
French
German
01/05/2009STUDY PUBLISHED IN THE LANCET SHOWS ERBITUX SIGNIFICANTLY IMPROVES OVERALL SURVIVAL IN 1ST-LINE NSCLC
Darmstadt, Germany
 English
30/04/2009

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis 
Geneva, Switzerland

 

English
German
French
Spanish
Italian

21/04/2009MERCK SERONO LAUNCHES Kuvan ® in europe
Geneva, Switzerland
 English
German
French
02/04/2009MERCK SERONO: PHASE III ERBITUX DATA PUBLISHED IN NEJM CONFIRMENHANCED EFFICACY IN MCRC PATIENTS IN THE 1ST-LINE SETTING
Darmstadt, Germany
 English
30/03/2009

Merck Serono: New Phase III Data for Cladribine Tablets
to Be Presented at the American Academy of Neurology
61st ANNUAL MEETING IN APRIL 2009
Geneva, Switzerland

 English
German
French
23/03/2009MERCK SERONO LAUNCHES STRATEGIC VENTURE CAPITAL FUND
Geneva, Switzerland
 English
German
French
18/03/2009

Merck Serono and  Fast Forward, LLCAnnounce Collaboration to Accelerate Development of Treatments for Multiple Sclerosis
Geneva, Switzerland

 English
German
French
24/02/2009MERCK SERONO AND AMBRX EXPAND COLLABORATION THROUGH ARX424 MULTIPLE SCLEROSIS DRUG DEVELOPMENT ALLIANCE
Geneva, Switzerland
 English
German
French
19/02/2009

EUROPEAN MEDICINES AGENCY RECOMMENDS SUSPENSION OF MARKETING AUTHORIZATION FOR RAPTIVA®
Geneva, Switzerland

 English
German
French
16/03/2009

MERCK SERONO EXPANDS CILENGITIDE DEVELOPMENT PROGRAM
Darmstadt, Germany

 English
03/02/2009

Merck Serono’s Safinamide Significantly Improved Motor Function in Patients with Advanced Parkinson’s Disease in a Phase III Pivotal Trial
Geneva, Switzerland

 English
German
French
23/01/2009MERCK SERONO LAUNCHES ERBITUX IN 1ST-LINE TREATMENT OF HEAD AND NECK CANCER IN EUROPE
Antwerp, Belgium
 English
23/01/2009MERCK SERONO´S ORAL INVESTIGATIONAL TREATMENT CLADRIBINE TABLETS FOR MULTIPLE SCLEROSIS SIGNIFICANTLY REDUCED RELAPSE RATE IN TWO-YEAR PHASE III PIVOTAL TRIAL
Geneva, Switzerland
 English
German
French
13/01/2009


MERCK SERONO AND APITOPE ANNOUNCE LICENSING AGREEMENT ON NOVEL PEPTIDE THERAPEUTICS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
Geneva, Switzerland
 English
German
French

SERVICES